Nonapnea sleep disorders and incident chronic kidney disease: A population-based retrospective cohort study

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Huang, Shih Ting ^a,b   Lin, Cheng Li ^c,d   Yu, Tung Min ^a,b   Yang, Te Cheng ^e   Kao, Chia Hung ^c,d  

^a Division of Nephrology Department of Medicine Taichung Veterans General Hospital   (China)

^b Pediatric Dentistry   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e KUANG TIEN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ICD-9; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONAPNEA SLEEP DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SLEEP DISORDER; TAIWAN; CASE CONTROL STUDY; HYPERLIPIDEMIAS; INCIDENCE; LONGITUDINAL STUDY; RENAL INSUFFICIENCY, CHRONIC; SLEEP DISORDERS; STROKE;

AGE FACTORS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEX FACTORS; SLEEP DISORDERS; STROKE; TAIWAN;

EID: 84938077414     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000429     Document Type: Article

References (42)

1. Levey AS, Stevens LA, Schmid C.H., et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604-612.
2. Levey AS, Schoolwerth AC, Burrows N.R., et al., Centers for Disease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009; 53:522-535.
3. Wen CP, Cheng TY, Tsai M.K., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008; 371:2173-2182.
4. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305:1553-1559.
5. Sarnak MJ, Levey AS, Schoolwerth A.C., et al., American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108:2154-2169.
6. Weiner DE, Tighiouart H, Griffith J.L., et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med. 2007; 120:552.e1-552.e8.
7. Tonelli M, Muntner P, Lloyd A., et al., Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380:807-814.
8. Chronic Kidney Disease Prognosis Consortium Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375:2073-2081.
9. Menon V, Wang X, Sarnak M.J., et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008; 73:1310-1315.
10. Packham DK, Alves TP, Dwyer J.P., et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012; 59:75-83.
11. Haroun MK, Jaar BG, Hoffman S.C., et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003; 14:2934-2941.
12. Hallan S, de Mutsert R, Carlsen S, et al. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis. 2006; 47:396-405.
13. Zhu P, Liu Y, Han L., et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014; 9:e100801.
14. Driver TH, Shlipak MG, Katz R, et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2014; 64:534-541.
15. Rayner HC, Baharani J, Dasgupta I., et al. Does community-wide chronic kidney disease management improve patient outcomes? Nephrol Dial Transplant. 2014; 29:644-649.
16. Floras JS. Sleep apnea and cardiovascular risk. J Cardiol. 2014; 63:3-8.
17. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc. 2004; 79:1036-1046.
18. Drager LF, Togeiro SM, Polotsky V.Y., et al. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013; 62:569-576.
19. Adeseun GA, Rosas SE. The impact of obstructive sleep apnea on chronic kidney disease. Curr Hypertens Rep. 2010; 12:378-383.
20. Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012; 60:929-935.
21. Vgontzas AN, Liao D, Pejovic S., et al. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care. 2009; 32:1980-1985.
22. Lai YJ, Lin CL, Lin M.C., et al. Population-based cohort study on the increase in the risk for type 2 diabetes mellitus development from nonapnea sleep disorders. Sleep Med. 2013; 14:913-918.
23. Huang WS, Tsai CH, Lin C.L., et al. Nonapnea sleep disorders are associated with subsequent ischemic stroke risk: a nationwide, population-based, retrospective cohort study. Sleep Med. 2013; 14:1341-1347.
24. Sivertsen B, Lallukka T, Salo P., et al. Insomnia as a risk factor for ill health: results from the large population-based prospective HUNT Study in Norway. J Sleep Res. 2014; 23:124-132.
25. Luyster FS, Kip KE, Buysse D.J., et al. Traditional and nontraditional cardiovascular risk factors in comorbid insomnia and sleep apnea. Sleep. 2014; 37:593-600.
26. Li Y, Zhang X, Winkelman J.W., et al. Association between insomnia symptoms and mortality: a prospective study of U.S. men. Circulation. 2014; 129:737-746.
27. Ahmad S, Gupta R, Dhyani M. Prevalence and correlates of insomnia and obstructive sleep apnea in chronic kidney disease. N Am J Med Sci. 2013; 5:641-646.
28. Hui DS, Wong TY, Ko F.W., et al. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000; 36:783-788.
29. Hirotsu C, Tufik S, Bergamaschi C.T., et al. Sleep pattern in an experimental model of chronic kidney disease. Am J Physiol Renal Physiol. 2010; 299:F1379-F1388.
30. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 6:97-111.
31. Hermes E, Rosenheck R. Prevalence, pharmacotherapy and clinical correlates of diagnosed insomnia among veterans health administration service users nationally. Sleep Med. 2014; 15:508-514.
32. Cheng TM. Taiwan's national health insurance system: high value for the dollar. In: Okma KGH, Crivelli L, eds. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific; 2009. 71-204.
33. Cheng CL, Kao YH, Lin SJ. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20:236-242.
34. Léger D, Massuel MA, Metlaine A. SISYPHE Study Group. Professional correlates of insomnia. Sleep. 2006; 29:171-178.
35. Daley M, Morin CM, LeBlanc M, et al. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009; 32:55-64.
36. Irwin M, Clark C, Kennedy B., et al. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun. 2003; 17:365-372.
37. Pejovic S, Vgontzas AN, Basta M, et al. Leptin and hunger levels in young healthy adults after one night of sleep loss. J Sleep Res. 2010; 19:552-558.
38. Sauvet F, Leftheriotis G, Gomez-Merino D, et al. Effect of acute sleep deprivation on vascular function in healthy subjects. J Appl Physiol. 2010; 108:68-75.
39. Nakazaki C, Noda A, Koike Y., et al. Association of insomnia and short sleep duration with atherosclerosis risk in the elderly. Am J Hypertens. 2012; 25:1149-1155.
40. Irwin M, Thompson J, Miller C., et al. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab. 1999; 84:1979-1985.
41. van Gool J, van Vugt H, Helle M, et al. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol. 1990; 57:200-210.
42. Ohkuma T, Fujii H, Iwase M., et al. Association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: the Fukuoka diabetes registry. PLoS One. 2013; 8:e78968.